Connection
Matthew J. Brady to Receptor, Insulin
This is a "connection" page, showing publications Matthew J. Brady has written about Receptor, Insulin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.491 |
|
|
|
-
Ou H, Yan L, Mustafi D, Makinen MW, Brady MJ. The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor. J Biol Inorg Chem. 2005 Dec; 10(8):874-86.
Score: 0.303
-
Sargis RM, Neel BA, Brock CO, Lin Y, Hickey AT, Carlton DA, Brady MJ. The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1 levels. Biochim Biophys Acta. 2012 Jun; 1822(6):952-60.
Score: 0.118
-
Brady MJ. IRS2 takes center stage in the development of type 2 diabetes. J Clin Invest. 2004 Oct; 114(7):886-8.
Score: 0.070